­
­
­
­

Inventi Impact: Pharm Analysis & Quality Assurance

Articles

  • Inventi:ppaqa/31428/20
    Development of UV Spectrophotometric Procedures for Determination of Amlodipine and Celecoxib in Formulation: Use of Scaling Factor to Improve the Sensitivity
    Research 2020 : April - June
    Mahesh Attimarad, Katharigatta Narayanaswamy Venugopala, Bandar E Aldhubiab, Anroop Balachandran Nair, Nagaraja SreeHarsha, Shinu Pottathil, Sabah H Akrawi

    FDA has recently approved a new fixed-dose combination of amlodipine besylate (AMD) and celecoxib (COX) for the treatment\nof hypertension and osteoarthritis. No analytical method has been reported for analysis of these two analytes so far. Hence, to\nmonitor the quality and quantity in the formulation of AMD and COX a simple, accurate, precise, economical, and eco-friendly\nspectroscopic analytical method has been established. The first method involves the determination of AMD and COX by the first\nderivative UV spectroscopic method with scaling factor 10������..

    How to Cite this Article
    Attribution/ CC Compliant Citation: Attimarad, Mahesh, et al. \"Development of UV Spectrophotometric Procedures for Determination\nof Amlodipine and Celecoxib in Formulation: Use of Scaling Factor to Improve the Sensitivity.\" Journal of Spectroscopy 2019 (2019).\nhttps://doi.org/10.1155/2019/8202160\nhttp://creativecommons.org/licenses/by/4.0/\nSome formatting elements, header, footer, logos, dates and pagination were modified while adapting this article.
    Download Full Text